Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Home » ELF Community Advisory Group attends UNITE4TB annual meeting
Members of the ELF Community Advisory Group (CAG) recently attended the UNITE4TB annual meeting from 6 to 8 May in London. They spoke about the group’s work to date, their plans for the year ahead and some of the challenges they have faced.
Members of the ELF Community Advisory Group (CAG) – Blessi Kumar, Paul Sommerfeld and Stephan Dressler – attended the UNITE4TB annual meeting in London from 6 to 8 May 2025. They spoke about the group’s work to date, their plans for the year ahead and some of the challenges they have encountered.
The CAG is a core part of the UNITE4TB project. It was established to allow for meaningful engagement with people affected by tuberculosis (TB) and ensure patients’ voices are considered throughout its activities. The group includes members from across the world who have either lived experience of TB or work with communities affected by it.
During the meeting, the CAG members explained why it is important to engage the patient community. This can bring many benefits to research, including:
They also highlighted wider challenges including global funding cuts, the need for greater diversity in clinical trials and the importance of reaching out to communities at trial sites.
Blessi also took part in a panel discussion on underserved groups in TB research. She emphasised the need to include children and pregnant women in clinical trials, noting that an estimated 1.3 million children and young people were diagnosed with TB in 2023.
More action should be taken to include these groups in research that could improve their treatment options. This would increase access to support for the disease and reduce health inequalities worldwide.
Sign up to get the latest information and research on lung conditions, hear about our upcoming events and campaigns, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79